This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs
by Zacks Equity Research
Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.
5 Stocks to Buy for Remarkable Earnings Growth in 2017
by Tirthankar Chakraborty
Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price
The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
by Zacks Equity Research
Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
by Zacks Equity Research
Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.
Theravance Stock Up on Fast Track Status for Velusetrag
by Zacks Equity Research
Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.
5 Best Small-Cap Stocks for 2017
by Swarup Gupta
Investing in small cap stocks with superior fundamentals will make for a profitable choice even in 2017.
Bristol-Myers Reports Data from Opdivo Combination Studies
by Zacks Equity Research
Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.
GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
by Zacks Equity Research
GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).
Acceleron, Celgene Present Myelodysplastic Syndromes Data
by Zacks Equity Research
Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.
Alexion Presents Data from Ultra-Rare Blood Disorder Study
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.
Heat Biologics Stock Falls on Negative Bladder Cancer Data
by Zacks Equity Research
Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.
Cytori Scleroderma Study Two-Year Follow-Up Data Published
by Zacks Equity Research
Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease
by Zacks Equity Research
PhaseRx (PZRX) received Orphan Drug status from the FDA for PRX-OTC for the treatment of rare liver disorder.
Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo Pharmaceuticals
This Value Screen Is Our Top Performer This Year
by Kevin Matras
See how this screen has blown past the market and how you can start using it in your own portfolio. Highlighted stocks include CIM, PFSI and SCMP.
Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and Alexandria Real Estate Equities
by Zacks Equity Research
Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and Alexandria Real Estate Equities
Zacks.com featured highlights: Lancaster Colony, Foot Locker, ULTA Salon, Cosmetics & Fragrance, Sucampo Pharmaceuticals and Fox Factory Holding
by Zacks Equity Research
Zacks.com featured highlights: Lancaster Colony, Foot Locker, ULTA Salon, Cosmetics & Fragrance, Sucampo Pharmaceuticals and Fox Factory Holding